Cargando…

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

Patched homolog 1 gene (PTCH1) expression and the ratio of PTCH1 to Smoothened (SMO) expression have been proposed as prognostic markers of the response of chronic myeloid leukemia (CML) patients to imatinib. We compared these measurements in a realistic cohort of 101 patients with CML in chronic ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alonso-Dominguez, Juan M., Casado, Luis Felipe, Anguita, Eduardo, Gomez-Casares, Maria Teresa, Buño, Ismael, Ferrer-Marín, Francisca, Arenas, Alicia, Del Orbe, Rafael, Ayala, Rosa, Llamas, Pilar, Salgado, Rocio N., Osorio, Santiago, Sanchez-Godoy, Pedro, Burgaleta, Carmen, Mahíllo-Fernández, Ignacio, Garcia-Gutierrez, Valentin, Steegmann, Juan Luis, Martinez-Lopez, Joaquín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5509313/ https://www.ncbi.nlm.nih.gov/pubmed/28704552 http://dx.doi.org/10.1371/journal.pone.0181366

Ejemplares similares

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
por: Casado, Luis-Felipe, et al.
Publicado: (2015)

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
por: Steegmann, Juan Luis, et al.
Publicado: (2017)

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
por: Steegmann, Juan Luis, et al.
Publicado: (2017)

Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14Ptch(FVB) mice
por: Kang, Hio Chung, et al.
Publicado: (2012)

Different Response of Ptch Mutant and Ptch Wildtype Rhabdomyosarcoma Toward SMO and PI3K Inhibitors
por: Geyer, Natalie, et al.
Publicado: (2018)

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
por: Marcé, Sílvia, et al.
Publicado: (2021)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Ptch2/Gas1 and Ptch1/Boc differentially regulate Hedgehog signalling in murine primordial germ cell migration
por: Kim, Yeonjoo, et al.
Publicado: (2020)

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
por: Hernández-Boluda, Juan Carlos, et al.
Publicado: (2018)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Role of PTCH1 gene methylation in gastric carcinogenesis
por: ZUO, YUN, et al.
Publicado: (2014)

Unexpected phenotype in a frameshift mutation of PTCH1
por: Beltrami, Benedetta, et al.
Publicado: (2019)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

A healthy individual with a homozygous PTCH2 frameshift variant: Are variants of PTCH2 associated with nevoid basal cell carcinoma syndrome?
por: Altaraihi, M., et al.
Publicado: (2019)

Author Correction: Ptch2/Gas1 and Ptch1/Boc differentially regulate Hedgehog signalling in murine primordial germ cell migration
por: Kim, Yeonjoo, et al.
Publicado: (2020)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Novel mutation in PTCH1 gene in a patient with basal cell nevus syndrome and uterus bicornis
por: Miyashiro, Denis, et al.
Publicado: (2019)

Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
por: Klein, Claudius, et al.
Publicado: (2016)

Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency
por: Hasanovic, Anida, et al.
Publicado: (2018)

Mutation of the PTCH1 gene predicts recurrence of breast cancer
por: Wang, Chih-Yang, et al.
Publicado: (2019)

Ptch2 is a Potential Regulator of Mesenchymal Stem Cells
por: Juuri, Emma, et al.
Publicado: (2022)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
por: Obeidat, Khaldun, et al.
Publicado: (2019)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Role of Extracellular Vesicles as Potential Diagnostic and/or Therapeutic Biomarkers in Chronic Cardiovascular Diseases
por: Martin-Ventura, Jose Luis, et al.
Publicado: (2022)

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
por: Garcia Gutierrez, Valentin, et al.
Publicado: (2023)

Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase
por: Malhotra, Hemant, et al.
Publicado: (2015)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

A novel PTCH1 mutation in a patient with Gorlin syndrome
por: Okamoto, Nana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7i06rjle66funup6s8ijf6m9ps